Business Wire

EUROPE-HIGH-GROWTH-FUND

12.2.2024 22:16:25 CET | Business Wire | Press release

Share
European High Growth Opportunities Securitization Fund Comments on Press Release Issued by Tony G Co-Investment Holdings Ltd.

European High Growth Opportunities Securitization Fund (the “Fund”), acting through and represented by European High Growth Opportunities Manco SA, each of which is an investment vehicle advised by Alpha Blue Ocean, responds to a press release dated February 1, 2024 issued by Tony G Co-Investment Holdings Ltd. (the “Company”), pursuant to which the Company asserted that it is not bound by its obligations under the terms of the $1,288,000 principal amount convertible debenture of the Company dated August 10, 2021 (the “Debenture”) and purported to issue shares to the Fund.

The Fund would like to notify shareholders of the Company that the Fund rejects the purported share issuance and continues to allege that the Company is bound by, and in breach of, its obligations under the Debenture. The Fund continues to pursue its claim against the Company which will be heard by the Ontario Superior Court of Justice (the “Court”) on November 22, 2024. The Fund reminds both management and the board of directors of the Company that they are bound by their fiduciary obligations to the Company and all stakeholders.

In addition, given the actions of the Company, its management and its board of directors, including Messrs. Antanas Guoga and Ron Akram, the Fund is currently exploring all other avenues of recourse available, including relief under the oppression remedy and relief available from the Canadian Securities Exchange (the “CSE”) and the Ontario Securities Commission with respect to this matter.

In the Fund’s opinion, the Company has failed to provide clear guidance to the market regarding its obligations under the Debenture and the claim that was commenced by the Fund or to comply with its obligations to issue press releases with respect to material changes. The Fund’s position is that:

  • As a result of the occurrence of several events of default under the Debenture and the underlying subscription agreement (including the Company’s failure to issue securities to the Fund in a timely manner and the Company’s securities being suspended from trading on the CSE on June 6, 2022), the Fund exercised its rights under the Debenture on November 21, 2022 and demanded the Company immediately pay the sum of $1,288,000 in cash pursuant to the terms of the Debenture;
  • Although the monies owed by the Company to the Fund accrue interest at a rate of 40% per annum, compounded monthly, the Company has flouted its obligation to repay the Fund for more than a year, focusing instead on the completion of a series of related party transactions that the Fund believes erode the value of stakeholders for the benefit of insiders;
  • On December 7, 2022, the Fund was forced to initiate a proceeding in the Court for, among other things, the payment of $1,288,000, plus interest at the rate of 40% per annum, compounded monthly; and
  • In November 2023, the Fund agreed to engage in settlement discussions with the Company and, as an illustration of the Fund’s good faith efforts to resolve the dispute, agreed to extend certain Court deadlines only to have the Company suddenly terminate settlement discussions through the unilateral purported issuance of shares to the Fund and accompanying press release on February 1, 2024, which the Fund believes misrepresents the Company’s liability.

The Fund denies the validity of the share issuance to the Fund and will continue to seek recourse against the Company through its litigation in the Court.

The Fund regrets needing to bring legal proceedings against the Company in order for the Company to comply with its obligations under the Debenture and wishes to put an expeditious end to these distractions.

About European High Growth Opportunities Securitization Fund

European High Growth Opportunities Securitization Fund is a fund based in Luxembourg which is in the business of investing in high growth companies.

Forward-looking statements

This press release contains forward-looking statements. All statements contained in this press release that are not clearly historical in nature or that necessarily depend on future events are forward-looking, and the words “anticipate,” “believe,” “expect,” “estimate,” “plan,” “intends,” and similar expressions are generally intended to identify forward-looking statements. These statements are based on current expectations of the Fund and currently available information. They are not guarantees of future performance, involve certain risks and uncertainties that are difficult to predict, and are based upon assumptions as to future events that may not prove to be accurate. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Fund’s ability to control or predict, that may cause the actual results to differ materially from those discussed in the forward-looking statements. Forward-looking statements in this press release include, among other things, statements regarding the intentions of the Fund with respect to the Debenture and the litigation (including any potential settlement thereof and the Company’s conduct in connection therewith). Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, that the litigation will be resolved in a manner that is unfavourable to the Company and that the Company will be required to pay amounts or issue shares to the Fund in defending, resolving, or in connection with, the litigation. The forward-looking statements included in this press release are made as of the date of this press release and the Fund does not assume any obligation to update any forward-looking statements contained in this press release, except as required by applicable law.

Neither the CSE nor its regulation services provider accepts responsibility for the adequacy or accuracy of this press release.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240212603262/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Okomera Announces a Commercial Agreement With Servier to Use Its Tumor Miniaturization Technology for Cancer Research21.10.2026 08:00:00 CEST | Press release

Okomera reaches a key milestone in its industrial rollout with the first commercial installation of its integrated platform, combining hardware, software and biology, in the laboratories of an international pharmaceutical group. Servier will use Okomera’s technology to evaluate new therapeutic approaches in oncology and immuno-oncology. Okomera, a TechBio company pioneering personalized cancer care through a proprietary technology platform combining tumor mini-avatars, microfluidics, and AI-powered imaging, today announced the signing of a commercial agreement with Servier, an independent international pharmaceutical group, to use its technology in the development of new cancer treatments. With more than 90% of oncology drug candidates never reaching the market, identifying early on the therapeutic approaches most likely to succeed is a critical challenge for the pharmaceutical industry. Okomera’s technology helps precisely reduce this attrition, by steering development toward candidat

Bureau Veritas: Double Digit Total Revenue Growth in the Third Quarter of 202621.10.2026 07:30:00 CEST | Press release

Organic revenue growth sequential improvement;2026 outlook confirmed Bureau Veritas (BOURSE:BVI): The execution of LEAP | 28 has transformed Bureau Veritas into a more focused, faster-growing and higher-performing multi-specialist company. Its Product Line-centric operating model combines the Company’s global scale and resilience with clear priorities, stronger accountability and deep specialist expertise. This creates a more repeatable growth model, enabling faster execution, stronger capabilities and higher conversion of growth into profitability. Q3 2026 Key figures1 › New reporting structure effective July 1st, 2026, comprising four divisions: Industrials & Commodities, Buildings & Infrastructure, Business Assurance, and Product Testing & Services, excluding the planned for exit businesses of Oil & Petrochemicals and Coal Testing and Inspection, and “Government Services”; › Revenue of EUR 1,569.7 million, up 10.1% year-on-year and up 6.2% organically; • Positive scope effect of 1.8

AI Emerges as CEOs' Most Critical Challenge, Egon Zehnder Study Finds21.10.2026 07:00:00 CEST | Press release

Third annual edition of The CEO Response finds leaders prioritizing AI and business alliances as demands on CEO leadership grow Artificial intelligence has emerged as the most critical challenge facing CEOs worldwide, ahead of geopolitical instability and economic uncertainty, according to The CEO Response, Egon Zehnder's third annual study of 843 global chief executives. Nearly half of CEOs (48%) consider the adoption and impact of AI an extremely critical challenge, up from 37% in 2025. Geopolitical instability (44%) and economic uncertainty (40%) follow, while 62% expect geopolitical disruption to increase over the next 12 months. These challenges are shaping where CEOs are focusing their efforts. Half (50%) identify AI investment among the three most important changes they're making to their organizations, followed by innovation (48%) and improving their cost base (41%). By comparison, 29% selected upskilling and talent development as a top priority. “CEOs can invest in AI much fas

AMWC Dubai 2026: Galderma Reinforces Its Injectable Aesthetics Leadership21.10.2026 07:00:00 CEST | Press release

Galderma will present eight posters spanning its full Injectable Aesthetics portfolio at AMWC Dubai 2026, highlighting the complementary benefits of Sculptra® and Restylane®, and pooled phase III study data for Relfydess® (relabotulinumtoxinA)1-8 With 30 years of innovation, Restylane continues to evolve through the development of new technologies and expanded clinical indications, with data to be presented from four studies across the chin, jawline, temples, and lower face Several Meet-the-Expert sessions and a symposium on the AART™ of Body, which highlights new expanded indications for Sculptra in the gluteal area, posterior thighs, and décolletage, follows Sculptra’s recent approval for use on the body in the United Arab Emirates (UAE)9 Galderma (SIX: GALD) will showcase data from its leading innovative Injectable Aesthetics portfolio at the Aesthetic & Anti-Aging Medicine World Congress (AMWC) taking place in Dubai, United Arab Emirates (UAE), from October 21-23, 2026. The company

Sihoo præsenterer næste generation af ergonomiske kontorløsninger på ORGATEC 202620.10.2026 20:12:00 CEST | Pressemeddelelse

Med ORGATEC 2026 lige om hjørnet vil Sihoo, specialist i ergonomiske sidde løsninger, præsentere sine næste generations løsninger til arbejdspladsen i hal 8.1, stand A-060 og B-061. I tråd med messens tema, »Fra rum til relationer: design af rum i en verden i konstant forandring«, vil Sihoo demonstrere, hvordan adaptivt ergonomisk design understøtter skiftende siddestillinger og nye behov på moderne arbejdspladser. Der er multimedier i denne pressemeddelelse. Se hele meddelelsen her: https://www.businesswire.com/news/home/20261020048673/da/ Sihoo på ORGATEC 2026 i Köln En oplevelseszone baseret på forskellige arbejdsscenarier Sihoos stand har et åbent layout, hvor en orange-hvid farvepalet kombineres med loftskonstruktioner i flere niveauer, halvgennemsigtige skillevægge og integreret belysning. Arbejdsstationer med højdejusterbare skriveborde og skærme samt siddeområder til samarbejde genskaber velkendte kontormiljøer og viser, hvordan ergonomiske stole passer ind på moderne arbejdspl

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye